Ovid Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Ovid Therapeutics

05/05/2023 17:23

* Ovid Therapeutics Inc  OVID.OQ   OVID.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 5
(estimated). 
    * The New York City-based  company is expected to report
revenue
of $22 thousand, according to the mean estimate from 3 analysts,
based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Ovid Therapeutics
Inc is
for a loss of 18 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 10.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $4.75​, above​ its last closing price of $3.65. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.17       -0.17      -0.19     Missed  -10.9
 Dec. 31 2023  -0.17       -0.18      -0.16     Beat    12.2
 Sep. 30 2022  -0.21       -0.21      -0.17     Beat    20.7​
 Jun. 30 2022  -0.25       -0.25      -0.21     Beat    15.6
 ​​Mar.        -0.20       -0.21      -0.23     Missed  -11
 31 2022                                                
 Dec. 31 2021  -0.15       -0.16      -0.10     Beat    38​
 Sep. 30 2021  -0.18       -0.18      -0.17     Beat    7.5
 Jun. 30 2021  -0.15       -0.16      -0.23     Missed  -42
 This summary was machine generated May 5 at 16:23 GMT.  All
figures in US dollars  unless otherwise stated